CTD^2 Pancancer Drug Activity DREAM Challenge
Learn More Over the course of two years, the Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive
IDG-DREAM Drug-Kinase Binding
Learn More Mapping the complete target space of drugs and drug-like compounds, including both intended ‘primary targets’ as well as secondary ‘off-targets’,
Multi-targeting Drug DREAM Challenge
Learn More Polypharmacology has key advantages for a host of diseases including cancer, diabetes, and Mendelian diseases. Recent data supports the view
AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge
Learn More Targeted therapies and personalized treatments are the most promising assets to treat cancer. However, in many patients, a tumor’s innate
DREAM 7 – NCI-DREAM Drug Sensitivity and Drug Synergy Challenge
Learn More Development of new cancer therapeutics currently requires a long and protracted process of experimentation and testing. Human cancer cell lines